Mirae Asset Multicap Fund
The scheme is seeks to provide long-term capital appreciation from a portfolio investing predominantly in Indian equity and equity related securities of large cap, mid cap and small cap companies
Growthvine rating: 3/5 — ranked #9 of 34 in category.
Fund basics
| Category | Equity: Multi Cap |
|---|
| NAV | ₹14.94 (as of 2026-08-21) |
|---|
| AUM | ₹5,278 Cr |
|---|
| Expense ratio | 1.59% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ankit Jain |
|---|
| Exit load | 1% for redemption within 365 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -18.67% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 97.1% of NIFTY500 Multicap 50:25:25's upside and 97.9% of its downside.
Market cap allocation
| Large cap | 36.2% |
|---|
| Mid cap | 31.1% |
|---|
| Small cap | 32.7% |
|---|
Concentration
| Top 5 holdings | 17.7% |
|---|
| Top 10 holdings | 28.3% |
|---|
| Total holdings | 78 |
|---|
| Index overlap | 32.0% |
|---|
| Active share | 68.0% |
|---|
Top holdings
- HDFC Bank Ltd. — 5.4%
- ICICI Bank Ltd. — 3.8%
- AXIS Bank Ltd. — 3.0%
- Delhivery Limited — 3.0%
- Reliance Industries Ltd — 2.5%
- Hero MotoCorp Limited — 2.3%
- Vedanta Aluminium Metal Limited — 2.2%
- Gland Pharma Limited — 2.1%
- DALMIA BHARAT LIMITED — 2.1%
- IndusInd Bank Ltd. — 2.0%
Top sectors
- Banking & Financial — 21.9%
- Automobile — 8.3%
- Pharma & Biotech — 7.9%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 1.1% | Q4 (Bottom) | #31 of 34 |
| 2025 | 8.3% | Q1 (Top) | #1 of 31 |
| 2024 | 17.1% | Q4 (Bottom) | #22 of 24 |